miscentertainmentcorporateresearchwellnessathletics

ノバルティスCEO、120億ドルの米バイオ企業買収は「取るべき適切なリスク」

By Bhanvi Satija

ノバルティスCEO、120億ドルの米バイオ企業買収は「取るべき適切なリスク」

Bhanvi is a London-based reporter covering European pharmaceutical companies and the healthcare industry. She previously covered U.S. health and pharma firms, with a focus on the new weight loss drugs that are transforming the obesity treatment space. Her coverage includes a trend piece on the underuse of their weight-loss drugs among men, increased interest in therapies being developed for preservation of lean mass, and a scoop on gene therapy maker Sarepta defying an FDA order to stop shipping its muscular dystrophy treatment.

Previous articleNext article

POPULAR CATEGORY

misc

18062

entertainment

19086

corporate

15851

research

9773

wellness

15784

athletics

20147